Venkata Krishna Enterprises Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-07-2024
- Paid Up Capital ₹ 0.18 M
as on 24-07-2024
- Company Age 14 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue 20.10%
(FY 2023)
- Profit 41.70%
(FY 2023)
- Ebitda 38.23%
(FY 2023)
- Net Worth 32.88%
(FY 2023)
- Total Assets 8.39%
(FY 2023)
About Venkata Krishna Enterprises
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.18 M, as per Ministry of Corporate Affairs (MCA) records.
Paidiwar Srinivas, Phani Ramella, and Udaya Tadepalli serve as directors at the Company.
- CIN/LLPIN
U51909TG2010PTC071012
- Company No.
071012
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Nov 2010
- Date of AGM
28 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Venkata Krishna Enterprises?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Paidiwar Srinivas  | Director | 02-Jul-2019 | Current |
| Phani Ramella | Director | 02-Jul-2019 | Current |
| Udaya Tadepalli | Director | 29-Sep-2021 | Current |
Financial Performance and Corporate Structure Insights of Venkata Krishna Enterprises.
Venkata Krishna Enterprises Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 20.1% increase. The company also saw a substantial improvement in profitability, with a 41.7% increase in profit. The company's net worth Soared by an impressive increase of 32.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Venkata Krishna Enterprises?
In 2023, Venkata Krishna Enterprises had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Sai Sridhar Pharma Private LimitedActive 17 years 2 months
Paidiwar Srinivas, Phani Ramella and 1 more are mutual person
- Wynclark Pharmaceuticals Private LimitedActive 17 years 10 months
Paidiwar Srinivas is a mutual person
- Deccan Medisales Private LimitedActive 13 years 6 months
Paidiwar Srinivas and Phani Ramella are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Venkata Krishna Enterprises?
Venkata Krishna Enterprises has a workforce of 21 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Venkata Krishna Enterprises, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Venkata Krishna Enterprises's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
